Condition: Pancreatic Neuroendocrine Tumor (pNET) · Extra-Pancreatic Neuroendocrine Tumor (epNET) · Sponsor: Exelixis
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
This description comes directly from the study's public registry record.
Exelixis Clinical Trials · 1-888-EXELIXIS (888-393-5494) · druginfo@exelixis.com
Backup or International · 650-837-7400
Always discuss trial participation with your own doctor first.
| The University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Mayo Clinic Hospital | Phoenix, Arizona, United States | Recruiting |
| The University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| Cedars-Sinai Medical Center | Beverly Hills, California, United States | Recruiting |
| Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Stanford Cancer Center | Palo Alto, California, United States | Recruiting |
| UCLA Health - Santa Monica Cancer Care | Santa Monica, California, United States | Recruiting |
| Kaiser Permanente Medical Center | Vallejo, California, United States | Recruiting |
| Georgetown University | Washington D.C., District of Columbia, United States | Recruiting |
| Mayo Clinic - Florida | Jacksonville, Florida, United States | Recruiting |
| AdventHealth Orlando | Orlando, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
+ 105 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06943755